Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 6,918 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Squamous Cell Carcinoma, Carcinoma of Head/Neck
Interventions: Taxotere, Cisplatin, 5-Fluorouracil, Leucovorin, G-CSF, Ciprofloxacin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Stimulant Use Disorder
Interventions: Repetitive transcranial magnetic stimulation (rTMS), Sham rTMS; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Normal Physiology
Interventions: In vivo MRS, fMRI, EEG/EOG, Stimulation tasks, NSPRD, Structural MRI; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: Algorithm based programming using Kinesia-based assessment; Device
Lead sponsor: Great Lakes NeuroTechnologies Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina • Columbus, Ohio

Conditions: COVID-19, SARS-CoV-2
Interventions: Sargramostim, Standard of care; Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Fullerton, California • Orange, California • San Francisco, California + 8 more

Conditions: Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions: Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally; Drug
Lead sponsor: li nguyen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Westminster, California

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Diffuse
Interventions: GM-CSF, CHOP, Rituximab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injury Cervical, Spinal Cord Injuries (Complete and Incomplete)
Interventions: Brain Computer Interface (BCI) - Functional Electrical Stimulation (FES) system; Device
Lead sponsor: Case Western Reserve University; Other
Eligibility: 22 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Aging
Interventions: Real tDCS, Sham tDCS; Other
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 65 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Roslindale, Massachusetts

Conditions: Fibromyalgia
Interventions: Active tDCS, Active Exercise, Sham tDCS, Sham Exercise; Device · Procedure
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2007
U.S. locations: 30
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 24 more

Conditions: Patellofemoral Pain Syndrome
Interventions: transcranial direct current stimulator; Device
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Myocardial Infarction, Tachyarrhythmia
Interventions: Parasym device (active, current (mA) < discomfort threshold), Parasym device (sham, current (mA) = 0); Device
Lead sponsor: Hippocration General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy
Interventions: Filgrastim; Drug
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 60 Years
Enrollment: 60,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2030
U.S. locations: 4
States / cities: Boca Raton, Florida • Rockville, Maryland • Minneapolis, Minnesota + 1 more

Conditions: Sleep
Interventions: transcranial direct current stimulation (tDCS), Sham; Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Multiple Sclerosis
Interventions: Active tDCS; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 23 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Mood Disorder, Bipolar Disorder, Major Depression, Depression
Interventions: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Davis, California

Conditions: Stroke
Interventions: repetitive transcranial magnetic stimulation (rTMS), peripheral sensory stimulation; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Schizophrenia, Hallucinations
Interventions: repetitive transcranial magnetic stimulation; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Autism Spectrum Disorder, Autism, Asperger Syndrome
Interventions: Transcranial magnetic stimulation; Device
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Neurological Disease, Parkinson Disease, Epilepsy
Interventions: DBS Stimulation during sleep; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Cytarabine, Filgrastim, Fludarabine, Idarubicin, Pegfilgrastim, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: Transcranial magnetic stimulation via MagPro x100 device; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-invasive Neuromodulation in Healthy Subjects
Interventions: Inhibitory rTMS (1 Hz), Excitatory rTMS (5 Hz); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 40 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Repetitive Transcranial Magnetic Stimulation Treatment of Stimulant Use Disorder

Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction

Automated Deep Brain Stimulation Programming Using Functional Mapping

Study of Sargramostim in Patients With COVID-19

ASIS for Botox in Upper Limb Spasticity

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Development of Optimal Sensory Feedback Strategies to Maximize Function After Tetraplegia

The Effects of Noninvasive Brain Stimulation on Physical and Mental Functioning in Older Adults

Optimized tDCS for Fibromyalgia: Targeting the Endogenous Pain Control System

Combination Chemotherapy in Treating Children With Lymphoma

Modulating Cortical Excitability to Improve Functional Movements in Individuals With Patellofemoral Pain

Transcutaneous Vagal Nerve Stimulation to Prevent Tachyarrhythmias in Patients Early Following Myocardial Infarction

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

The Effect of tDCS Applied During Sleep on Memory Consolidation

Cognitive Markers in Prodromal MS

A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression

Can rTMS Enhance Somatosensory Recovery After Stroke?

Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations

Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Cerebellar rTMS for the Treatment of Schizophrenic Patients

Mechanisms of Non-Invasive Neuromodulation Interventions: Influence on Human Neurochemistry and Functional Connectivity